tiprankstipranks
Advertisement
Advertisement
Lyell Immunopharma Shareholders Back Governance at 2026 Meeting
PremiumCompany AnnouncementsLyell Immunopharma Shareholders Back Governance at 2026 Meeting
2M ago
Lyell Immunopharma provides update on safety profile of LYL273
Premium
The Fly
Lyell Immunopharma provides update on safety profile of LYL273
2M ago
Lyell Gains Buy Rating on Leadership in CD19/20 CAR-T and Ronde-cel Progress; Analyst Reiterates $45 Price Target
Premium
Ratings
Lyell Gains Buy Rating on Leadership in CD19/20 CAR-T and Ronde-cel Progress; Analyst Reiterates $45 Price Target
3M ago
Lyell Immunopharma Stock (LYEL) Slides Despite Praise from a Top Wall Street Analyst
PremiumMarket NewsLyell Immunopharma Stock (LYEL) Slides Despite Praise from a Top Wall Street Analyst
4M ago
Lyell Immunopharma: Undervalued CAR-T Innovator With Strong Ronde-cel Profile, Hidden LYL273 Upside, and Cash Runway to 2027 Supporting Buy Rating and $44 Target
Premium
Ratings
Lyell Immunopharma: Undervalued CAR-T Innovator With Strong Ronde-cel Profile, Hidden LYL273 Upside, and Cash Runway to 2027 Supporting Buy Rating and $44 Target
4M ago
Lyell Immunopharma initiated with a Buy at Needham
Premium
The Fly
Lyell Immunopharma initiated with a Buy at Needham
4M ago
LYEL Earnings this Week: How Will it Perform?
PremiumPre-EarningsLYEL Earnings this Week: How Will it Perform?
5M ago
Lyell Immunopharma Advances GCC19CART Trial in Metastatic Colorectal Cancer: What Investors Should Know
Premium
Company Announcements
Lyell Immunopharma Advances GCC19CART Trial in Metastatic Colorectal Cancer: What Investors Should Know
5M ago
Lyell Immunopharma: Differentiated CAR-T Durability and Second-Line LBCL Opportunity Underpin Buy Rating and $45 Target
Premium
Ratings
Lyell Immunopharma: Differentiated CAR-T Durability and Second-Line LBCL Opportunity Underpin Buy Rating and $45 Target
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100